| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VSIG4 |
| Uniprot No | Q9Y279 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-283aa |
| 氨基酸序列 | RPILEVPESVTGPWKGDVNLPCTYDPLQGYTQVLVKWLVQRGSDPVTIFL RDSSGDHIQQAKYQGRLHVSHKVPGDVSLQLSTLEMDDRSHYTCEVTWQT PDGNQVVRDKITELRVQKLSVSKPTVTTGSGYGFTVPQGMRISLQCQARG SPPISYIWYKQQTNNQEPIKVATLSTLLFKPAVIADSGSYFCTAKGQVGS EQHSDIVKFVVKDSSKLLKTKTEAPTTMTYPLKATSTVKQSWDWTTDMDG YLGETSAGPGKSLPVDHHHHHH |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VSIG4重组蛋白的模拟参考文献示例(注：内容为虚构，仅作格式参考，实际文献需通过学术数据库查询)：
1. **文献名称**: *"VSIG4 Recombinant Protein Suppresses T-cell Activation via Complement Receptor Signaling"*
**作者**: Zhang Y, Chen L, Wang X
**摘要**: 研究通过体外实验证明，重组VSIG4蛋白可通过结合补体成分(如C3b/C3c)抑制T细胞增殖及炎症因子分泌，提示其作为免疫检查点在自身免疫疾病中的治疗潜力。
2. **文献名称**: *"Targeting VSIG4 with Recombinant Protein Enhances Anti-tumor Immunity in Solid Tumors"*
**作者**: Kim H, Park S, Jung M
**摘要**: 在小鼠模型中，重组VSIG4蛋白通过调控肿瘤相关巨噬细胞(TAMs)的极化，减少免疫抑制性细胞因子分泌，从而增强PD-1抑制剂疗效，为癌症联合治疗提供新策略。
3. **文献名称**: *"Structural and Functional Characterization of Recombinant Human VSIG4 in Inflammatory Bowel Disease"*
**作者**: Müller R, Schmidt A, Braun J
**摘要**: 该研究解析了重组VSIG4蛋白的晶体结构，并验证其通过阻断TLR4/NF-κB通路减轻结肠炎模型中的肠道炎症，支持VSIG4作为炎症性肠病的潜在治疗靶点。
4. **文献名称**: *"VSIG4 Recombinant Protein Attenuates Sepsis by Modulating Macrophage Phagocytosis and Cytokine Storm"*
**作者**: Li Q, Zhou T, Xu F
**摘要**: 实验表明，重组VSIG4蛋白可增强巨噬细胞对病原体的吞噬能力，同时抑制过度炎症反应，显著提高脓毒症小鼠的生存率，揭示了其在感染性疾病中的双重调节作用。
**建议**：以上为模拟内容，实际文献请通过PubMed、Web of Science等平台以关键词“VSIG4 recombinant protein”或“VSIG4 immune function”检索，并关注近年高影响力期刊(如*Nature Immunology*, *Journal of Immunology*)的相关研究。
VSIG4 (V-set and immunoglobulin domain-containing protein 4), also known as CRIg (complement receptor of the immunoglobulin superfamily), is a B7 family-related immune checkpoint protein involved in regulating T-cell activation and immune homeostasis. It is a transmembrane protein predominantly expressed on tissue-resident macrophages and dendritic cells. Structurally, VSIG4 contains an extracellular V-type immunoglobulin (Ig) domain and a C1-set Ig domain, which mediate its interaction with ligands or receptors on immune cells. Functionally, VSIG4 acts as a negative regulator of T-cell responses by suppressing T-cell proliferation and cytokine production, likely through an unidentified receptor-ligand mechanism. It also serves as a receptor for complement component C3b/C3c, linking innate and adaptive immunity by modulating phagocytosis and inflammation.
Recombinant VSIG4 protein, produced via genetic engineering in systems like mammalian or insect cell lines, retains the functional domains necessary for immune modulation. This engineered protein is widely used in biomedical research to investigate VSIG4’s role in autoimmune diseases, chronic inflammation, and cancer. For instance, studies suggest VSIG4 overexpression in tumor-associated macrophages may contribute to an immunosuppressive tumor microenvironment, making it a potential therapeutic target. In preclinical models, blocking VSIG4 with monoclonal antibodies or recombinant antagonists has shown enhanced anti-tumor immunity and reduced inflammatory damage in autoimmune conditions like rheumatoid arthritis.
The development of recombinant VSIG4 also aids in structural studies, ligand identification, and drug screening. Its dual role in complement signaling and T-cell inhibition positions it as a unique candidate for therapies aiming to balance immune activation and tolerance. Current research focuses on optimizing its therapeutic potential while minimizing off-target effects, highlighting its significance in next-generation immunotherapy development.
×
